Trials
1 active
7 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.”In the company’s words, NCT06782555 on ClinicalTrials.gov
- Tested for
- Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Main trialPhase 1/2
- “The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).”In the company’s words, NCT06782555 on ClinicalTrials.gov
- Other names
- TH-302 · HAP · hypoxia activated prodrug
- Given with
- Gemzar (Lilly)Other companies’ drugs in its trials
Other drugs for Metastatic Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone AcetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamideAstellas · Pfizer · Phase 3
- MevrometostatPfizer · Phase 3
Coming up1
- Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Oct 2027 | A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab | |
| Phase 3Completed | Feb 2016 | Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | |
| Phase 2Completed | Sep 2013 | Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma | |
| Phase 2Terminated | Sep 2015 | A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | |
| Phase 2Terminated | Apr 2016 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer | |
| Phase 1/2Completed | Jul 2013 | Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma | |
| Phase 1Terminated | Sep 2015 | Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026